2018 and De-Escalation - Healthcare Support Central

Doing Less Can Be Doing More for Healthcare – the Biggest Takeaway From ASCO 2018

Health Populi

JUNE 5, 2018

The study, Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, was published in The New England Journal of Medicine on June 3, 2018, coinciding with the researchers’ ASCO presentation of the results. We are de-escalating toxic therapy.”

De-Escalation

De-Escalation Admissions Hospital Tests

Three Critiques of the DanGer-Shock Trial

Sensible Medicine

JUNE 3, 2024

However, in October 2018, 5.5 Abiomed, the manufacturer of the device, joined the trial at that time (2018). It would be very useful if the authors had reported the time that elapsed from randomization until the decision to escalate to a device was made in both groups. What is the reason for this low inclusion? A Coruña.

De-Escalation

De-Escalation Hospital Follow-Up

Healthcare Support Central

Doing Less Can Be Doing More for Healthcare – the Biggest Takeaway From ASCO 2018

Three Critiques of the DanGer-Shock Trial

Webinars

Stay Connected